Aminolevulinic acid-mediated photodynamic therapy of human meningioma: An in vitro study on primary cell lines

International Journal of Molecular Sciences

Volumn 16, Issue 5, 2015, Pages 9936-9948

  El Khatib, Mustafa ^a   Tepe, Carolin ^a   Senger, Brigitte ^a   Dibué Adjei, Maxine ^a,b   Riemenschneider, Markus Johannes ^c   Stummer, Walter ^d   Steiger, Hans Jakob ^a   Cornelius, Jan Frédérick ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

5 ALA; Aminolevulinic acid; In vitro; Meningioma; PDT; Photodynamic therapy; Primary cell culture

Indexed keywords

AMINOLEVULINIC ACID; EPITHELIAL MEMBRANE ANTIGEN; PORPHYRIN; TETRAZOLIUM; TRYPSIN; MUCIN 1;

ADULT; AGED; ARTICLE; CELL SURVIVAL; CELL VIABILITY ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LD50; MALE; MENINGIOMA; PHOTODYNAMIC THERAPY; PRIMARY CELL LINE; DOSE RESPONSE; DRUG EFFECTS; MENINGEAL NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOTOCHEMOTHERAPY; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; MUCIN-1; PHOTOCHEMOTHERAPY;

EID: 84929377650     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16059936     Document Type: Article

References (46)

1. Longstreth, W.T., Jr.; Dennis, L.K.; McGuire, V.M.; Drangsholt, M.T.; Koepsell, T.D. Epidemiology of intracranial meningioma. Cancer 1993, 72, 639–648.
2. Riemenschneider, M.J.; Perry, A.; Reifenberger, G. Histological classification and molecular genetics of meningiomas. Lancet Neurol. 2006, 5, 1045–1054.
3. Rockhill, J.; Mrugala, M.; Chamberlain, M.C. Intracranial meningiomas: An overview of diagnosis and treatment. Neurosurg. Focus 2007, 23, E1.
4. Kuratsu, J.; Kochi, M.; Ushio, Y. Incidence and clinical features of asymptomatic meningiomas. J. Neurosurg. 2000, 92, 766–770.
5. Mirimanoff, R.O.; Dosoretz, D.E.; Linggood, R.M.; Ojemann, R.G.; Martuza, R.L. Meningioma: Analysis of recurrence and progression following neurosurgical resection. J. Neurosurg. 1985, 62, 18–24.
6. Simpson, D. The recurrence of intracranial meningiomas after surgical treatment. J. Neurol. Neurosurg. Psychiatry 1957, 20, 22–39.
7. Stafford, S.L.; Perry, A.; Suman, V.J.; Meyer, F.B.; Scheithauer, B.W.; Lohse, C.M.; Shaw, E.G. Primarily resected meningiomas: Outcome and prognostic factors in 581 mayo clinic patients, 1978 through1988. Mayo Clin. Proc. 1998, 73, 936–942.
8. Marosi, C.; Hassler, M.; Roessler, K.; Reni, M.; Sant, M.; Mazza, E.; Vecht, C. Meningioma. Crit. Rev. Oncol. Hematol. 2008, 67, 153–171.
9. Ohgari, Y.; Nakayasu, Y.; Kitajima, S.; Sawamoto, M.; Mori, H.; Shimokawa, O.; Matsui, H.; Taketani, S. Mechanisms involved in δ-aminolevulinic acid (ALA)-induced photosensitivity of tumor cells: Relation of ferrochelatase and uptake of ALA to the accumulation of protoporphyrin. Biochem. Pharmacol. 2005, 71, 42–49.
10. Whittle, I.R.; Smith, C.; Navoo, P.; Collie, D. Meningiomas. Lancet 2004, 363, 1535–1543.
11. El-Khatib, M.; El Majdoub, F.; Hoevels, M.; Kocher, M.; Muller, R.P.; Steiger, H.J.; Sturm, V.; Maarouf, M. Stereotactic linac radiosurgery for incompletely resected or recurrent atypical and anaplastic meningiomas. Acta Neurochir. 2011, 153, 1761–1767.
12. Kondziolka, D.; Lunsford, L.D.; Coffey, R.J.; Flickinger, J.C. Stereotactic radiosurgery of meningiomas. J. Neurosurg. 1991, 74, 552–559.
13. Kondziolka, D.; Mathieu, D.; Lunsford, L.D.; Martin, J.J.; Madhok, R.; Niranjan, A.; Flickinger, J.C. Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery 2008, 62, 53–58.
14. Stafford, S.L.; Pollock, B.E.; Foote, R.L.; Link, M.J.; Gorman, D.A.; Schomberg, P.J.; Leavitt, J.A. Meningioma radiosurgery: Tumor control, outcomes, and complications among 190 consecutive patients. Neurosurgery 2001, 49, 1029–1037.
15. Hefti, M.; von Campe, G.; Moschopulos, M.; Siegner, A.; Looser, H.; Landolt, H. 5-aminolevulinic acid induced protoporphyrin IX fluorescence in high-grade glioma surgery: A one-year experience at a single institutuion. Swiss Med. Wkly. 2008, 138, 180–185.
16. Kennedy, J.C.; Marcus, S.L.; Pottier, R.H. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): Mechanisms and clinical results. J. Clin. Laser Med. Surg. 1996, 14, 289–304.
17. Stummer, W.; Gotz, C.; Hassan, A.; Heimann, A.; Kempski, O. Kinetics of photofrin II in perifocal brain edema. Neurosurgery 1993, 33, 1075–1081.
18. Stummer, W.; Hassan, A.; Kempski, O.; Goetz, C. Photodynamic therapy within edematous brain tissue: Considerations on sensitizer dose and time point of laser irradiation. J. Photochem. Photobiol. B 1996, 36, 179–181.
19. Stummer, W.; Pichlmeier, U.; Meinel, T.; Wiestler, O.D.; Zanella, F.; Reulen, H.J.; ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol. 2006, 7, 392–401.
20. Beck, T.J.; Kreth, F.W.; Beyer, W.; Mehrkens, J.H.; Obermeier, A.; Stepp, H.; Stummer, W.; Baumgartner, R. Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX. Lasers Surg. Med. 2007, 39, 386–393.
21. Hirschberg, H.; Sun, C.H.; Tromberg, B.J.; Madsen, S.J. ALA- and ALA-ester-mediated photodynamic therapy of human glioma spheroids. J. Neurooncol. 2002, 57, 1–7.
22. Olzowy, B.; Hundt, C.S.; Stocker, S.; Bise, K.; Reulen, H.J.; Stummer, W. Photoirradiation therapy of experimental malignant glioma with 5-aminolevulinic acid. J. Neurosurg. 2002, 97, 970–976.
23. Stepp, H.; Beck, T.; Pongratz, T.; Meinel, T.; Kreth, F.W.; Tonn, J.; Stummer, W. ALA and malignant glioma: Fluorescence-guided resection and photodynamic treatment. J. Environ. Pathol. Toxicol. Oncol. 2007, 26, 157–164.
24. Tsai, J.C.; Hsiao, Y.Y.; Teng, L.J.; Chen, C.T.; Kao, M.C. Comparative study on the ALA photodynamic effects of human glioma and meningioma cells. Lasers Surg. Med. 1999, 24, 296–305.
25. Castano, A.P.; Demidova, T.N.; Hamblin, M.R. Mechanisms in photodynamic therapy: Part one—Photosensitizers, photochemistry and cellular localization. Photodiagn. Photodyn. Ther. 2004, 1, 279–293.
26. Castano, A.P.; Demidova, T.N.; Hamblin, M.R. Mechanisms in photodynamic therapy: Part two—cellular signaling, cell metabolism and modes of cell death. Photodiagn. Photodyn. Ther. 2005, 2, 1–23.
27. Eljamel, M.S.; Goodman, C.; Moseley, H. ALA and photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: A single centre phase III randomised controlled trial. Lasers Med. Sci. 2008, 23, 361–367.
28. Hebeda, K.M.; Saarnak, A.E.; Olivo, M.; Sterenborg, H.J.; Wolbers, J.G. 5-aminolevulinic acid induced endogenous porphyrin fluorescence in 9l and c6 brain tumours and in the normal rat brain. Acta Neurochir. 1998, 140, 503–512.
29. Morofuji, Y.; Matsuo, T.; Hayashi, Y.; Suyama, K.; Nagata, I. Usefulness of intraoperative photodynamic diagnosis using 5-aminolevulinic acid for meningiomas with cranial invasion: Technical case report. Neurosurgery 2008, 62, 102–103.
30. Krammer, B.; Plaetzer, K. ALA and its clinical impact, from bench to bedside. Photochem. Photobiol. Sci. 2008, 7, 283–289.
31. Ferreira, G.C.; Gong, J. 5-Aminolevulinate synthase and the first step of heme biosynthesis. J. Bioenerg. Biomembr. 1995, 27, 151–159.
32. Kajimoto, Y.; Kuroiwa, T.; Miyatake, S.; Ichioka, T.; Miyashita, M.; Tanaka, H.; Tsuji, M. Use of 5-aminolevulinic acid in fluorescence-guided resection of meningioma with high risk of recurrence. Case report. J. Neurosurg. 2007, 106, 1070–1074.
33. Hefti, M.; Holenstein, F.; Albert, I.; Looser, H.; Luginbuehl, V. Susceptibility to 5-aminolevulinic acid based photodynamic therapy in who i meningioma cells corresponds to ferrochelatase activity. Photochem. Photobiol. 2011, 87, 235–241.
34. Coluccia, D.; Fandino, J.; Fujioka, M.; Cordovi, S.; Muroi, C.; Landolt, H. Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas. Acta Neurochir. 2010, 152, 1711–1719.
35. Marks, P.V.; Furneaux, C.; Shivvakumar, R. An in vitro study of the effect of photodynamic therapy on human meningiomas. Br. J. Neurosurg. 1992, 6, 327–332.
36. Cornelius, J.F.; Slotty, P.J. Meningioma surgery in the era of 5-aminolevulinic acid fluorescence-guided surgery. J. Neurosurg. 2014, 121, 766.
37. Cornelius, J.F.; Slotty, P.J.; El Khatib, M.; Giannakis, A.; Senger, B.; Steiger, H.J. Enhancing the effect of 5-aminolevulinic acid based photodynamic therapy in human meningioma cells. Photodiagn. Photodyn. Ther. 2014, 11, 1–6.
38. Cornelius, J.F.; Slotty, P.J.; Kamp, M.A.; Schneiderhan, T.M.; Steiger, H.J.; El-Khatib, M. Impact of 5-aminolevulinic acid fluorescence-guided surgery on the extent of resection of meningiomas—With special regard to high-grade tumors. Photodiagn. Photodyn. Ther. 2014, 11, 481–490.
39. Bekelis, K.; Valdes, P.A.; Erkmen, K.; Leblond, F.; Kim, A.; Wilson, B.C.; Harris, B.T.; Paulsen, K.D.; Roberts, D.W. Quantitative and qualitative 5-aminolevulinic acid-induced protoporphyrin IX fluorescence in skull base meningiomas. Neurosurg. Focus 2011, 30, E8.
40. Hefti, M. Comment concerning: Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas, Acta Neurochir doi 1o.1007/s00701-010-0708-4, intratumoral heterogeneity and fluorescence intensity in meningioma after 5-ALA pretreatment. Acta Neurochir. 2011, 153, 959–960.
41. Pfisterer, W.K.; Hank, N.C.; Preul, M.C.; Hendricks, W.P.; Pueschel, J.; Coons, S.W.; Scheck, A.C. Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas. Neuro-Oncology 2004, 6, 290–299.
42. Sayagues, J.M.; Tabernero, M.D.; Maillo, A.; Espinosa, A.; Rasillo, A.; Diaz, P.; Ciudad, J.; Lopez, A.; Merino, M.; Goncalves, J.M. et al. Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (fish): Is there a relationship between histopathologically benign and atypical/anaplastic lesions? J. Mol. Diagn. 2004, 6, 316–325.
43. Kennedy, J.C.; Pottier, R.H. Endogenous protoporphyrin ix, a clinically useful photosensitizer for photodynamic therapy. J. Photochem. Photobiol. B 1992, 14, 275–292.
44. Inoue, K.; Karashima, T.; Kamada, M.; Shuin, T.; Kurabayashi, A.; Furihata, M.; Fujita, H.; Utsumi, K.; Sasaki, J. Regulation of 5-aminolevulinic acid-mediated protoporphyrin IX accumulation in human urothelial carcinomas. Pathobiology 2009, 76, 303–314.
45. Louis, D.N.; Ohgaki, H.; Wiestler, O.D.; Cavenee, W.K.; Burger, P.C.; Jouvet, A.; Scheithauer, B.W.; Kleihues, P. The 2007 who classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114, 97–109.
46. Hardy, S.J.; Christodoulides, M.; Weller, R.O.; Heckels, J.E. Interactions of neisseria meningitidis with cells of the human meninges. Mol. Microbiol. 2000, 36, 817–829.